CSF metabolomic signatures across five proteomic subtypes in patients with Alzheimer's disease
AD proteomic subtypes exhibit different CSF metabolomic alterations, reflecting heterogeneous pathophysiological mechanisms. This profiling could inform future subtype-specific therapies targeting metabolism. For example, therapies modulating glucose metabolism, typically tested in general AD populations, may be most effective for patients in S3.
Authors
- Lianne M. Reus (ORCID: https://orcid.org/0000-0001-6936-242X)
- P. J. Visser
- Yolande A.L. Pijnenburg (ORCID: https://orcid.org/0000-0003-2464-1905)
- Betty M. Tijms
- RA Ophoff
- Georgia Malliou
- Charlotte E. Teunissen
- Wiesje M. van der Flier
Institutions
- University of California, Los Angeles (US)
- Transnational University Limburg (NL)
- Karolinska Institutet (SE)
- Maastricht University (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_101527
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00